Popular Articles

Gene Test Determines Transplant Drug Tolerance
A simple genetic test can determine a kidney transplant patient"s tolerance for a potent anti-rejection medication, according to an upcoming study in the Journal of the American Society Nephrology (JASN). The test could allow doctors to individualize each patient"s dose, optimizing the drug"s benefits and minimizing its side effects.

Tummy Troubles -- Gastrin Key In Bacterial-Induced Stomach Cancer
Current research suggests that levels of gastrin play a key role in the development of Helicobacter-induced stomach cancer. The related report by Takaishi et al, "Gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice," appears in the July 2009 issue of The American Journal of Pathology.
News of the day
Pennsylvania House Approves Bill Allowing Young Adults To Remain On Parents' Health Insurance Policies Up To Age 29
The Pennsylvania House last week voted to approve a bill that allows state residents up to age 29 to be added to or remain on their parents" health insurance plans as long as they live in the state or are full-time students, the Harrisburg Patriot-News reports. They also must be single and not have dependents.According to national data, young adults between ages 19 and 29 make up the largest segment of the U.S. population without health insurance. The Pennsylvania Insurance Department estimates that nearly 400,000 state residents in that age group are uninsured. The bill allows employers to decide if they want to offer the coverage option to their employees. Families choosing to add adult dependents to their health plans will have higher premiums. Gov. Ed Rendell (D) is expected to sign the bill, which the state Senate approved in March (Thompson, Harrisburg Patriot-News, 5/14). Prescription for Pennsylvania Plan
Oncology

Conference: Discovery Partnerships: Academia & Industrial Interactions

Opal Events is proud to present our next exciting conference Drug Discovery Partnerships: Academia & Industrial Interactions , to be held at the Hyatt Regency in Boston on October 28-30, 2009. Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs. With key products suffering patent expiration in coming years, the need for new approaches to accelerate development of new chemical entities to treat severely unmet medical needs is more urgent than ever. This event brings together pharmaceutical companies, universities, small biotechnology enterprises, government agencies, for-profit and not-for profit research institutions to exchange ideas, make connections and discuss opportunities to create an environment that will foster pharmaceutical innovation. Overcome Your Most Critical Challenges in forming Academia-Industrial Partnerships: - Understand Specific Requirements Regarding Investigational New Drug (IND) Application and Approval Process - Maximize the Value and Minimize the Risk by Partnering with the Right Entity - Hear Insider"s Guide to Securing Grant Money for Your Drug Discovery Project - Examine Recent United States Decisions and their Impact on Pharmaceutical and Academia Patenting - Improve Speed to Market with Seamless Alignment on Science and Technology Who Will Attend? Pharmaceuticals, Biotechs, Academia, Foundations, Technology Companies and CRO"s - Managers/ Directors/ VP"s/ Faculty Advisors of: - External Research Collaboration - Scientific Affairs - Business Development - Partnership/ Alliance Management - Office of Technology Transfer - Academic Screening Facilities - School of Medicine/ Life Sciences/ Pharmacy - Grants Manager - Program Officer - Research & Development Sponsorship and Exhibiting Opportunities If you are interested in sponsorship, exhibiting or speaking opportunities, please contact Kay Ye at kye@opalevents.org or 212 532-9898, extension 263. Register Registration is already open on our website here. Sign up today! Opal Events


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):